PL418144A1 - Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego - Google Patents
Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubegoInfo
- Publication number
- PL418144A1 PL418144A1 PL418144A PL41814416A PL418144A1 PL 418144 A1 PL418144 A1 PL 418144A1 PL 418144 A PL418144 A PL 418144A PL 41814416 A PL41814416 A PL 41814416A PL 418144 A1 PL418144 A1 PL 418144A1
- Authority
- PL
- Poland
- Prior art keywords
- mir
- large intestine
- micrometastases
- increased risk
- intestine cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Przedmiotem zgłoszenia są nowe markery obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, u chorych po radykalnym leczeniu chirurgicznym, polegający na jednoczesnej ocenie ilości (ekspresji) wymienionych miRNA w materiale biologicznym. Przedmiotem zgłoszenia są również geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego, które stanowią następującą sygnaturę ekspresji: miR-24T, miR-126, miR-200c, miR-26a, let-7g, miR-27a, miR-152, miR-324-3p, miR-197, miR-1274B, miR-720, miR-1274A, miR-1825, miR-93#, miR-664, miR-30e-3p, miR-1285, miR-335#. Przedmiotem zgłoszenia są również są sposoby wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, u chorych po radykalnym leczeniu chirurgicznym, polegający na badaniu zaburzeń ekspresji genów.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL418144A PL418144A1 (pl) | 2016-07-29 | 2016-07-29 | Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego |
EP17001302.3A EP3276009A1 (en) | 2016-07-29 | 2017-07-28 | Microrna expression markers for crc development |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL418144A PL418144A1 (pl) | 2016-07-29 | 2016-07-29 | Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego |
Publications (1)
Publication Number | Publication Date |
---|---|
PL418144A1 true PL418144A1 (pl) | 2018-02-12 |
Family
ID=59811047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL418144A PL418144A1 (pl) | 2016-07-29 | 2016-07-29 | Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3276009A1 (pl) |
PL (1) | PL418144A1 (pl) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109825596B (zh) * | 2019-04-19 | 2022-03-15 | 中国医学科学院肿瘤医院 | 食管癌样本的内参miRNA及其应用 |
CN111057769A (zh) * | 2020-01-20 | 2020-04-24 | 广东医科大学 | 一种检测与结直肠癌易感相关的miR-218基因位点的试剂盒及其应用方法 |
CN113035358A (zh) * | 2021-04-08 | 2021-06-25 | 南京市第一医院 | 一种预测早期结肠癌患者预后风险的模型构建方法 |
CN113981096A (zh) * | 2021-11-30 | 2022-01-28 | 无锡市疾病预防控制中心 | 一种用于诊断结直肠癌的血浆miRNA标志物及其应用 |
CN114317743A (zh) * | 2021-12-23 | 2022-04-12 | 广西百谷生物科技有限公司 | 一种用于结直肠癌预后的miRNA检测试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011311881A1 (en) * | 2010-10-08 | 2013-05-02 | Baylor Research Institute | MicroRNAs (miRNA) as biomakers for the identification of familial and non-familial colorectal cancer |
US20140141986A1 (en) * | 2011-02-22 | 2014-05-22 | David Spetzler | Circulating biomarkers |
EP2771487A1 (en) * | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
EP2804959A2 (en) * | 2012-01-16 | 2014-11-26 | Herlev Hospital | Micrornas for prediction of treatment efficacy and prognosis of cancer patients |
-
2016
- 2016-07-29 PL PL418144A patent/PL418144A1/pl unknown
-
2017
- 2017-07-28 EP EP17001302.3A patent/EP3276009A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3276009A1 (en) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL418144A1 (pl) | Nowy marker obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego, sposób wykrywania obecności mikroprzerzutów i podwyższonego ryzyka nawrotu raka jelita grubego oraz geny normalizacyjne do normalizacji wyników ekspresji miRNA w tkance raka jelita grubego | |
Raza et al. | MicroRNAs: master regulators of drug resistance, stemness, and metastasis | |
Bebelman et al. | Biogenesis and function of extracellular vesicles in cancer | |
Wang et al. | Up-regulation of p21WAF1/CIP1 by miRNAs and its implications in bladder cancer cells | |
Xu et al. | MicroRNA-7–regulated TLR9 signaling–enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway | |
Shi et al. | miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGγ | |
BR112019009925A2 (pt) | método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . | |
Kovacs et al. | MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats | |
Tamagawa et al. | Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma | |
Wang et al. | MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines | |
Xin et al. | miR‑99 inhibits cervical carcinoma cell proliferation by targeting TRIB2 | |
SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
Ghafouri-Fard et al. | MicroRNA signature in melanoma: biomarkers and therapeutic targets | |
Adil et al. | Targeting Akt-associated microRNAs for cancer therapeutics | |
Rezaei et al. | miRNA signature in glioblastoma: Potential biomarkers and therapeutic targets | |
Liu et al. | Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer | |
Calvin Li et al. | Tissue elasticity bridges cancer stem cells to the tumor microenvironment through microRNAs: Implications for a “watch-and-wait” approach to cancer | |
Huang et al. | Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases | |
Santangelo et al. | Functional roles and therapeutic applications of exosomes in hepatocellular carcinoma | |
Fernandez-Mercado et al. | MicroRNAs in lymphoma: regulatory role and biomarker potential | |
Benetatos et al. | DLK1-MEG3 imprinted domain microRNAs in cancer biology | |
Ghafouri-Fard et al. | Expression of non-coding RNAs in hematological malignancies | |
EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
Lin et al. | SPINKL, a Kazal-type serine protease inhibitor-like protein purified from mouse seminal vesicle fluid, is able to inhibit sperm capacitation | |
Huang et al. | MicroRNA-133b negatively regulates zebrafish single Mauthner-cell axon regeneration through targeting TPPP3 in vivo |